On March 28, 2022, the Ninth Circuit affirmed a federal trial court’s grant of summary judgment to the manufacturer of a leading diabetes therapy. The decision was a victory for WLF, which filed an amicus brief in the case. The case arose from multi-district litigation (MDL) combining lawsuits by users of incretin-based therapies for type-2 diabetes. Novo Nordisk Inc. manufactures and markets Victoza (liraglutide). The plaintiffs complained that Victoza’s FDA-approved labeling failed to warn of an increased risk of pancreatic cancer. But, as WLF argued in its brief, and the Ninth Circuit rightly held, the plaintiffs offered no reliable evidence to establish general causation. Without admissible proof of causation, the plaintiffs’ claims must fail on the merits.